CO2024007518A2 - Injectable and inhalable formulations - Google Patents
Injectable and inhalable formulationsInfo
- Publication number
- CO2024007518A2 CO2024007518A2 CONC2024/0007518A CO2024007518A CO2024007518A2 CO 2024007518 A2 CO2024007518 A2 CO 2024007518A2 CO 2024007518 A CO2024007518 A CO 2024007518A CO 2024007518 A2 CO2024007518 A2 CO 2024007518A2
- Authority
- CO
- Colombia
- Prior art keywords
- dimethyltryptamine
- compound
- formulations
- optionally substituted
- aqueous pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a formulaciones farmacéuticas acuosas, métodos para su producción y usos de las mismas. Las formulaciones farmacéuticas acuosas comprenden una sal de un compuesto de dimetiltriptamina opcionalmente sustituida y agua, con un pH de 5 a 6.5, preferentemente de aproximadamente 5 a aproximadamente 6, y una concentración del compuesto de dimetiltriptamina opcionalmente sustituida de aproximadamente 10 mg/ml o mayor como el equivalente de base libre. Estas formulaciones pueden comprender una dosis efectiva de un compuesto de dimetiltriptamina opcionalmente sustituida para usarse en terapia psicodélica asistida dentro de un volumen de 5 ml o menos. Estas formulaciones son sorprendentemente adecuadas tanto para inyección intramuscular como para inhalación nebulizada, siendo tanto estables como clínicamente aceptables, y tienen usos potenciales en el tratamiento de trastornos psiquiátricos o neurológicos.The present invention relates to aqueous pharmaceutical formulations, methods for their production and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, having a pH of 5 to 6.5, preferably about 5 to about 6, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg/ml or greater as the free base equivalent. These formulations may comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in assisted psychedelic therapy within a volume of 5 ml or less. These formulations are surprisingly suitable for both intramuscular injection and nebulized inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW110143066A TWI891942B (en) | 2020-12-01 | 2021-11-18 | Deuterated compounds |
| PCT/EP2021/082227 WO2022117359A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| GBGB2119021.0A GB202119021D0 (en) | 2021-11-18 | 2021-12-24 | Injectable and inhalable formulations |
| US202217574424A | 2022-01-12 | 2022-01-12 | |
| EP2022055324 | 2022-03-02 | ||
| PCT/EP2022/082486 WO2023089132A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024007518A2 true CO2024007518A2 (en) | 2024-07-29 |
Family
ID=84440034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0007518A CO2024007518A2 (en) | 2021-11-18 | 2024-06-14 | Injectable and inhalable formulations |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4433049A1 (en) |
| JP (1) | JP2024540527A (en) |
| KR (1) | KR20240110836A (en) |
| AU (1) | AU2022393234A1 (en) |
| CA (1) | CA3238583A1 (en) |
| CL (1) | CL2024001452A1 (en) |
| CO (1) | CO2024007518A2 (en) |
| IL (1) | IL312859A (en) |
| MX (1) | MX2024005955A (en) |
| WO (1) | WO2023089132A1 (en) |
| ZA (1) | ZA202403906B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022553135A1 (en) | 2020-05-19 | 2024-03-04 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2666149A1 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| US20220071958A1 (en) * | 2019-02-22 | 2022-03-10 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| PT3873883T (en) | 2019-11-07 | 2023-03-24 | Small Pharma Ltd | SYNTHESIS METHOD |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| AU2021334933B2 (en) * | 2020-08-28 | 2023-01-19 | Cybin Uk Ltd | Injectable formulation |
| IL303288A (en) * | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
-
2022
- 2022-11-18 JP JP2024529536A patent/JP2024540527A/en active Pending
- 2022-11-18 EP EP22818741.5A patent/EP4433049A1/en active Pending
- 2022-11-18 MX MX2024005955A patent/MX2024005955A/en unknown
- 2022-11-18 AU AU2022393234A patent/AU2022393234A1/en active Pending
- 2022-11-18 WO PCT/EP2022/082486 patent/WO2023089132A1/en not_active Ceased
- 2022-11-18 KR KR1020247020007A patent/KR20240110836A/en active Pending
- 2022-11-18 IL IL312859A patent/IL312859A/en unknown
- 2022-11-18 CA CA3238583A patent/CA3238583A1/en active Pending
-
2024
- 2024-05-15 CL CL2024001452A patent/CL2024001452A1/en unknown
- 2024-05-20 ZA ZA2024/03906A patent/ZA202403906B/en unknown
- 2024-06-14 CO CONC2024/0007518A patent/CO2024007518A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202403906B (en) | 2025-08-27 |
| KR20240110836A (en) | 2024-07-16 |
| EP4433049A1 (en) | 2024-09-25 |
| WO2023089132A1 (en) | 2023-05-25 |
| AU2022393234A1 (en) | 2024-06-06 |
| CL2024001452A1 (en) | 2024-09-27 |
| MX2024005955A (en) | 2024-06-11 |
| CA3238583A1 (en) | 2023-05-25 |
| IL312859A (en) | 2024-07-01 |
| JP2024540527A (en) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eshraghi et al. | Enhancing autophagy in Alzheimer's disease through drug repositioning | |
| ES2708756T3 (en) | Materials and methods to improve lung function and for the prevention and / or treatment of radiation-induced lung complications | |
| ES2897453T3 (en) | Application of R-ketamine and salt thereof as pharmaceuticals | |
| ES2281439T3 (en) | USE OF AMINO ACID BASED ANTI-CONVULSIONS TO TREAT PAIN. | |
| ES2381664T3 (en) | Combinations of metabotropic glutamate receptor antagonists and their use in the treatment of addictive disorders | |
| ES2705698T3 (en) | Combination therapy for cancer treatment comprising eribulin and lenvatinib | |
| MX2021005969A (en) | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR. | |
| ECSP045140A (en) | Pharmaceutical formulations derived from platinum | |
| AR077484A1 (en) | FORMULATION OF GLATIRAMER ACETATE OF REDUCED VOLUME AND METHODS FOR ADMINISTRATION | |
| MX395136B (en) | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF ADMINISTRATION. | |
| JP2017533276A (en) | Methods for treating cognitive decline | |
| CO2024007518A2 (en) | Injectable and inhalable formulations | |
| RU2014150942A (en) | TREATMENT OF SIDE EFFECTS IN THE FORM OF MOTOR AND MOTOR DISORDERS RELATED TO THE TREATMENT OF PARKINSON'S DISEASE | |
| ES2383433T3 (en) | Pharmaceutical formulation of apomorphine for oral administration | |
| AR080096A1 (en) | COMBINED TREATMENT OF PANCREAS CANCER WITH GEMCITABIN AND MASITINIB | |
| ES2283406T3 (en) | INTRACORPORE MEDICINES FOR HIGH ENERGY PHOTOTHERAPEUTIC TREATMENT. | |
| ES2984490T3 (en) | Composition containing nicotine for the treatment of nasal or paranasal mucosal bleeding | |
| ES2276818T3 (en) | AGENT CONTAINING N-CHLOROTAURINE, AS WELL AS ITS USE FOR THE TREATMENT OF MUCOSA POLIPOS. | |
| ES2952367T3 (en) | Therapeutic conjugates based on PAR-1 and uses thereof | |
| US20210015934A1 (en) | Method of Treating Parkinson's Disease | |
| US20180235940A1 (en) | Treatment and management of augmentation in restless legs syndrome | |
| Natalini et al. | Analgesic and cardiopulmonary effects of epidural romifidine and morphine combination in horses | |
| ES2309105T3 (en) | USE OF S- (2,3-BISPALMITOILOXI- (2RS) -PROPIL) -CISTEINIL-GNNDESNISFKEK (MALP-2). | |
| Yesmin et al. | Experimental models and behavioral parameters for evaluation of Parkinson disease | |
| Milne | Nitrous oxide (laughing gas) inhalation as an alternative to electroconvulsive therapy |